Corvus Pharmaceuticals, which develops immuno-oncology therapies that utilize the immune system to fight cancer cells, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
The Washington, D.C.-based company, which was founded in 2014, plans to list on the Nasdaq under the symbol CRVS. Corvus Pharmaceuticals filed confidentially on 11/6/2015. Credit Suisse, Cowen & Company and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
